February 2015 Research Highlights

Brian Wojciechowski, M.D.

February 19, 2015

In this Breastcancer.org podcast, Brian Wojciechowski, M.D., Breastcancer.org’s medical adviser, discusses Ibrance, a medicine that was approved to treat metastatic, hormone-receptor-positive breast cancer in February 2015. Listen to the podcast to hear Dr. Wojciechowski explain:

how Ibrance works

who is eligible to take Ibrance

how Ibrance is taken and whether any other medicines are taken with it

the side effects that Ibrance can cause

Running time: 9:55

These podcasts, along with all the other vital content and community
support at Breastcancer.org, only exist because of the generous
donations of listeners like you. Please visit Breastcancer.org/support to learn how you can help keep our services free for you and the millions of women who depend on us.

Show Full Transcript

Jamie DePolo:
Hello, and welcome to the Breastcancer.org February 2015 Research News podcast. I’m your host, Jamie DePolo, the
senior editor of Breastcancer.org. Our guest today is Dr. Brian Wojciechowski, Breastcancer.org’s medical adviser.
And the topic today is the medicine Ibrance, which was just granted accelerated approval by the U.S. Food and Drug
Administration. So, to get started, Dr. Brian, let’s go over the basics of Ibrance: Who is it for? How is it given,
and how does it work?

Dr. Brian Wojciechowski:
So, the basics about Ibrance is that it’s a new oral drug, so it’s taken by mouth, in combination with a drug that
is already on the market for breast cancer, and that’s Femara, which is a hormonal therapy that many of our readers
are going to be familiar with already. Ibrance is something called a kinase inhibitor, and what it inhibits is the
cell cycle protein CDK4/6. What’s the cell cycle? Well, one of the things a cancer cell needs to do in order to
grow and spread is divide, and the process of cell division is called the cell cycle. So, this drug inhibits that
cell cycle, so it inhibits the process of cancer cells dividing and growing.

Jamie DePolo:
Okay.

Dr. Brian Wojciechowski:
The patients who are going to be able to take this medication are patients with advanced or metastatic breast
cancer who have not yet had a hormonal therapy. And this could be someone who is recently diagnosed with advanced
breast cancer that is hormone-receptor-positive, so estrogen- and progesterone-receptor-positive. It could be
someone who had early-stage breast cancer in the past and has now had a recurrence. It could also be a man if he
has breast cancer and his cancer is hormone-receptor-positive, and he now has advanced or metastatic disease. Some
patients will have already had chemotherapy before their hormone therapy, and this drug would also be appropriate
for those patients as well.

Jamie DePolo:
Let me just clarify, too, because I know some people have had questions. So, say I’m a woman, I was diagnosed with
early-stage, hormone-receptor-positive breast cancer that was treated with hormonal therapy. Now the cancer has
come back, it’s metastatic. Am I still eligible for Ibrance?

Dr. Brian Wojciechowski:
Yes.

Jamie DePolo:
Okay, so it’s the metastatic disease that has not been treated with hormonal therapy before.

Dr. Brian Wojciechowski:
That’s exactly right, Jamie.

Jamie DePolo:
Okay, okay perfect. And, also, I want to point out that because it’s always given with Femara, a person would never
take Ibrance alone, correct?

Dr. Brian Wojciechowski:
That’s correct according to the FDA indication.

Jamie DePolo:
Okay, so this would be, then, for postmenopausal women.

Dr. Brian Wojciechowski:
Yes, certainly anyone taking this would have to be postmenopausal.

Jamie DePolo:
Okay, okay great. Now, how long do people take Ibrance?

Dr. Brian Wojciechowski:
Since the drug is for advanced or metastatic disease, the patient would take it until it’s no longer working. So,
your doctor would do periodic assessments including scans, physical exams, or lab work, and when it’s determined
that the cancer is growing despite the drug, that’s when you would stop it and perhaps change to something else.

Jamie DePolo:
Okay. And as I understand it, too, Ibrance is a little bit different than some of the other hormonal therapies in
that you take it in cycles.

Dr. Brian Wojciechowski:
That’s right. Typically, for hormonal drugs, for example, like Femara or Arimidex or Aromasin, a patient is taking
it every day continuously. But Ibrance is different in the sense that you’re taking it once a day for 21 days, then
you get a 7 day break, and then you start all over again. And that’s considered one cycle. So, one cycle lasts for
28 days.

Jamie DePolo:
Okay. And it’s also my understanding, too, so if a person were on Ibrance they would take it for that 21 days. They
would not take it for the 7 days, but while that 7 days were going on where they were not taking Ibrance they would
still take the Femara, correct?

Dr. Brian Wojciechowski:
That’s correct.

Jamie DePolo:
Okay, perfect. Now, what about side effects?

Dr. Brian Wojciechowski:
Yes, so side effects of this drug most commonly would include trouble with blood counts, so decreased red blood
cells, which is also called anemia, and that affects the energy and the oxygen carried in the body. And also
decreased white blood cells, which can make you more susceptible to infection. If patients do get into problems
with decreased blood cells, what can be done is that the dose of the drug can be decreased with the next cycle, and
that usually helps.

Jamie DePolo:
Okay. Are there any other… I would guess, less severe -- what are the most common side effects? Is anemia and low
white blood cell count, are those very common with Ibrance or are those some of the more severe ones?

Dr. Brian Wojciechowski:
Those are fairly common. I think probably more common would be just plain fatigue. A severe side effect of Ibrance
includes pulmonary embolism, which is blood clots in the arteries of the lungs, which can be life-threatening.

Jamie DePolo:
Okay, okay.

Dr. Brian Wojciechowski:
And you certainly would not want to take this drug if you were pregnant.

Jamie DePolo:
Right, right, I had read that as well. Okay, so we talked about the side effects. We’ll talk a little bit about the
insurance coverage for that at the end, but before we get to there I wanted to ask you, what does accelerated
approval mean, and will there be other trials or studies on Ibrance?

Dr. Brian Wojciechowski:
Well, that’s a great question. So, the FDA has several different programs to get important drugs to the market
quicker than they otherwise would. Accelerated approval is when the FDA approves a drug based on non-traditional
endpoints, or what we would consider somewhat inferior data. So, Ibrance, for example, is approved based on a
benefit in progression-free survival, so the amount of time that women live without the cancer progressing or
getting worse. It was not based on overall survival benefit, meaning how long the patient lived until they died.
So, the FDA thought this drug was important enough and new enough, and they thought the preliminary data was good
enough that they gave it this designation and approved it. Now, there’s an ongoing study called the PALOMA trial.
PALOMA is the name of the trial. It also happens to mean "dove" in Spanish. And depending on the results of this
study, this large study, if the results look good, then the drug will receive traditional FDA approval. But if it
does not look good then the drug could be subject to being taken off the market at that point.

Jamie DePolo:
Oh, okay.

Dr. Brian Wojciechowski:
But it does get the drugs to patients sooner than it otherwise would.

Jamie DePolo:
Okay, okay, and I should point out that if anybody listening was in a clinical trial to test this medicine, it was
called palbociclib, so you may have heard us talk about that earlier. Before it was being marketed and approved, it
did not have a brand name, so it was just known by its chemical name, which is palbociclib, and now it’s called
Ibrance. So also, if you’re looking on the Breastcancer.org website for information, there are some older research
studies that talk about palbociclib. So just so everybody knows that. Now as far as insurance coverage, insurance
is going to cover this, but you do need to go through a specialty pharmacy and talk to your doctor and work with
your doctors and the special pharmacy to ensure that your insurance company is covering it and that you get it
delivered to your home and things like that, correct?

Dr. Brian Wojciechowski:
Yes, it is a very expensive drug. It’s a specialty drug, and you can’t get this at the corner drug store.

Jamie DePolo:
Okay. And it’s my understanding, too, so when you work with a specialty pharmacy, the navigator there then kind of
works with you and the medicine is actually delivered to your home.

Dr. Brian Wojciechowski:
Yes, that’s usually how it works. Some doctors have navigators they work with in their own office. I know that when
my patients get drugs like this they’re going to work with my navigator and my nurses as a team with the specialty
pharmacy, and the drug gets approved and delivered to the patient’s home usually within a week or two of
prescribing it.

Jamie DePolo:
Okay perfect. Well, thank you so much, Dr. Brian. This has been very illuminating. Is there anything else that
we’ve overlooked about Ibrance?

Dr. Brian Wojciechowski:
No, I just think this is a very exciting drug. The preliminary data is very strong and very promising, and my
expectation is that this will change the standard of care.

Jamie DePolo:
Okay, okay, well, thank you very much, and please everyone tune in next month when we’ll talk about another
Research News topic.